$SSKN News

New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA’s Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo

STRATA Skin Sciences Confirms Nasdaq Delisting

STRATA Skin Sciences Delists From Nasdaq

STRATA Skin Sciences Delists From Nasdaq

Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser

Strata Skin Sciences Partners with Johns Hopkins to Expand Access to Targeted Skin Treatments

STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis

STRATA Skin Sciences shares are trading lower. The company announced findings from a meta-analysis confirming the clinical efficacy of 308 nm Excimer laser in plaque psoriasis.

STRATA Skin Sciences Confirms Clinical Efficacy Of 308 NM Excimer Laser In Plaque Psoriasis

Laseroptek America Files Counterclaims Alleging Anticompetitive and Unfair Business Practices in Ongoing Litigation with Strata Skin Sciences

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico

Strata Skin Sciences Inc (SSKN) Q3 2025 Earnings Call Highlights: Navigating Challenges and ...

STRATA Skin (SSKN) Earnings Call Transcript

STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

STRATA Skin Sciences, Inc. (SSKN) Q3 2025 Earnings Call Transcript

Strata Skin Sciences Q3 EPS $(0.36) Beats $(0.39) Estimate, Sales $6.929M Miss $8.226M Estimate

A Peek at Strata Skin Sciences's Future Earnings

STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion

STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update

STRATA Skin Sciences Rises 25% Pre-Market — Here's Why